SYNTHESIS OF NOVEL HMG-COA REDUCTASE INHIBITORS .1. NAPHTHALENE ANALOGS OF MEVINOLIN

被引：0
作者：
NOVAK, L
ROHALY, J
POPPE, L
HORNYANSZKY, G
KOLONITS, P
ZELEI, I
FEHER, I
FEKETE, J
SZABO, E
ZAHORSZKY, U
JAVOR, A
SZANTAY, C
机构：
[1] TECH UNIV BUDAPEST, INST ORGAN CHEM, SZT GELLERT TER 4, H-1521 BUDAPEST, HUNGARY
[2] HUNGARIAN ACAD SCI, CENT RES INST CHEM, H-1525 BUDAPEST, HUNGARY
[3] TECH UNIV BUDAPEST, INST GEN & ANALYT CHEM, H-1521 BUDAPEST, HUNGARY
[4] UNIV KARLSRUHE, INST ORGAN CHEM, W-7500 KARLSRUHE 1, GERMANY
[5] GEDEON RICHTER CHEM WORKS LTD, H-1103 BUDAPEST, HUNGARY
来源：
LIEBIGS ANNALEN DER CHEMIE | 1992年 / 02期
关键词：
HMG-COA REDUCTASE INHIBITORS; NAPHTHYLACETATES; PIG LIVER ESTERASE; GLUTARATE; 3-HYDROXY; LACTONES;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The title compounds 2 and their corresponding (6S) epimers 18 are prepared in several steps by starting with chiral formyl ester 5, and alpha-tetralones 10: (1) coupling reaction with the ylide generated from 11 to yield unsaturated ester 13, (2) reduction to the corresponding alcohol 14, (3) addition of the Grignard reagent derived from 14 to formyl ester 5 to afford the hydroxy esters 16 and 17, and (4) lactonization. This procedure is also used to synthesize the beta-naphthyl analogs 29 and 30. Some results obtained from HMG-CoA reductase inhibitor screening are also reported.
引用
收藏
页码：145 / 157
页数：13
相关论文
共 50 条
  • [41] HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
    Bruno Bockorny
    Constantin A. Dasanu
    Annals of Hematology, 2015, 94 : 1 - 12
  • [42] Cataract and HMG-CoA reductase inhibitor: a case report
    Bousquet, E
    Amar, J
    Salvador, M
    Chamontin, B
    THERAPIE, 1998, 53 (05): : 505 - 507
  • [43] Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-Negative rods
    Farmer, Aaron R.
    Murray, Clinton K.
    Mende, Katrin
    Akers, Kevin S.
    Zera, Wendy C.
    Beckius, Miriam L.
    Yun, Heather C.
    JOURNAL OF BASIC MICROBIOLOGY, 2013, 53 (04) : 336 - 339
  • [44] Is the efficacy of HMG-CoA reductase inhibitors dependent on baseline plasma cholesterol-level?
    Cleophas, TJ
    van Marum, R
    Niemeijer, MG
    CLINICAL RESEARCH AND REGULATORY AFFAIRS, 2003, 20 (03) : 341 - 348
  • [45] Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: A review of recent developments
    Mac Neil, P
    CANADIAN JOURNAL OF CARDIOLOGY, 1998, 14 : 14A - 16A
  • [46] HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis
    Liu, Jie
    Zhu, Li-Ping
    Yang, Xu-Li
    Huang, He-Lang
    Ye, Dong-Qing
    BONE, 2013, 54 (01) : 151 - 156
  • [47] HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis
    Alana, Nicholas B.
    Ciurylo, William A.
    Hurlock, Natalie
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (02) : 260 - 268
  • [48] HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis
    Nicholas B. Alana
    William A. Ciurylo
    Natalie Hurlock
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 260 - 268
  • [49] Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors
    Liebhaber, MI
    Wright, RS
    Gelberg, HJ
    Dyer, Z
    Kupperman, JL
    CHEST, 1999, 115 (03) : 886 - 889
  • [50] HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
    Bockorny, Bruno
    Dasanu, Constantin A.
    ANNALS OF HEMATOLOGY, 2015, 94 (01) : 1 - 12
12345